Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 23 citing articles:

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review
Nadine S. van den Ende, Anh H. Nguyen, Agnes Jager, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2969-2969
Open Access | Times Cited: 99
Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer
Timothy B. Fisher, Geetanjali Saini, T. S. Rekha, et al.
Breast Cancer Research (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 11
Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis
Yue Chai, Yujie Chen, Di Zhang, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 2, pp. 323-323
Open Access | Times Cited: 26
Metabolomics insights into doxorubicin and 5-fluorouracil combination therapy in triple-negative breast cancer: a xenograft mouse model study
Mohamed Y. Hassanein, Yousra A. Hagyousif, Ruba A. Zenati, et al.
Frontiers in Molecular Biosciences (2025) Vol. 11
Open Access
Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy
Sabine Matou‐Nasri, M Sarawatense Aldawood, Fatimah Alanazi, et al.
Diagnostics (2023) Vol. 13, Iss. 14, pp. 2390-2390
Open Access | Times Cited: 11
A Comprehensive Analysis of Neoadjuvant Chemotherapy in Breast Cancer: Adverse Events, Clinical Response Rates, and Surgical and Pathological Outcomes—Bozyaka Experience
Cengiz Yılmaz, Baha Zengel, Orhan Üreyen, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 163-163
Open Access
Treatment Patterns, Trends, and Outcomes of Neoadjuvant Chemotherapy Use Among Patients With Early-Stage Invasive Triple-Negative Breast Cancer
Inimfon Jackson, Xiudong Lei, Catalina Malinowski, et al.
JCO Oncology Practice (2025)
Closed Access
Gemcitabine‐Loaded Injectable Hydrogel for Localized Breast Cancer Immunotherapy
Mahdieh Shokrollahi Barough, Amir Seyfoori, Esfandyar Askari, et al.
Advanced Functional Materials (2024)
Open Access | Times Cited: 3
A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer
Xiaomeng Jia, Kainan Wang, Lingzhi Xu, et al.
The Breast (2022) Vol. 66, pp. 31-39
Open Access | Times Cited: 8
Genomic Index of Sensitivity to Chemotherapy for Triple Negative Breast Cancer
Ahammad Sameer C, Manan Shah, Dipayan Nandy, et al.
Asian Pacific Journal of Cancer Prevention (2023) Vol. 24, Iss. 6, pp. 2043-2053
Open Access | Times Cited: 4
The analysis of transcriptomic signature of TNBC – searching for the potential RNA-based predictive biomarkers to determine the chemotherapy sensitivity
Stanisław Supplitt, Paweł Karpiński, Maria Sąsiadek, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Preoperative Differentiation of HER2‐Zero and HER2‐Low from HER2‐Positive Invasive Ductal Breast Cancers Using BI‐RADS MRI Features and Machine Learning Modeling
Jiejie Zhou, Yang Zhang, Haiwei Miao, et al.
Journal of Magnetic Resonance Imaging (2024)
Closed Access | Times Cited: 1
Investigation of the Effects and Mechanisms of Anticancer Action of a Ru(II)‐Arene Iminophosphorane Compound in Triple Negative Breast Cancer Cells
Nazia Nayeem, Arefa Yeasmin, Samantha N. Cobos, et al.
ChemMedChem (2021) Vol. 16, Iss. 21, pp. 3280-3292
Open Access | Times Cited: 7
The analysis of transcriptomic signature of TNBC—searching for the potential RNA-based predictive biomarkers to determine the chemotherapy sensitivity
Stanisław Supplitt, Paweł Karpiński, Maria Sąsiadek, et al.
Journal of Applied Genetics (2024)
Open Access
Effectiveness and safety of neoadjuvant therapy in triple-negative breast cancer in a real-world population
Cristina Galindo García, Rocío Díaz Acedo, Silvia Artacho Criado, et al.
Farmacia Hospitalaria (2024) Vol. 48, Iss. 6, pp. 278-285
Open Access
Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer
Maria Fernanda Império Pereira, Isabela Buzatto, Hélio Angotti Neto, et al.
Revista Brasileira Ginecologia e Obstetrícia (2024) Vol. 46
Open Access
Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine
Saif Khan, Suresh Babu Jandrajupalli, Nashwa Zaki Ali Bushara, et al.
Cells (2024) Vol. 13, Iss. 24, pp. 2126-2126
Open Access
Electroporation enhances cell death in 3D scaffold-based MDA-MB-231 cells treated with metformin
Praveen Sahu, Ignacio G. Camarillo, Monica Dettin, et al.
Bioelectrochemistry (2024) Vol. 159, pp. 108734-108734
Open Access
[Artículo traducido] Efectividad y seguridad del tratamiento neoadyuvante del cáncer de mama triple negativo en la vida real
Cristina Galindo García, Rocío Díaz Acedo, Silvia Artacho Criado, et al.
Farmacia Hospitalaria (2024) Vol. 48, Iss. 6, pp. T278-T285
Open Access
Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: the NOBROLA phase 2 study
Alfonso Cortés, Elena López-Miranda, Adela Fernández-Ortega, et al.
The Breast (2024) Vol. 78, pp. 103834-103834
Open Access
Dose-dense neoadjuvant chemotherapy in triple-negative breast cancer: Real-world data from a developing country
Rakesh Kumar Sharma, Ajay Gogia, S. V. S. Deo, et al.
Indian Journal of Cancer (2023) Vol. 60, Iss. 4, pp. 505-511
Open Access | Times Cited: 1
Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC
Wei‐Pang Chung, Chun‐Ting Yang, Shuen‐Ru Yang, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access
Cardiovascular pharmacotherapy in patients with triple negative breast cancer before and after anthracycline treatment
Anna Bartáková, Ivana Koloušková, Miloš Holánek, et al.
Klinicka onkologie (2023) Vol. 36, Iss. Suppl 1
Open Access
Page 1

Scroll to top